Surgical Specification and Efficacy Evaluation of Total Laparoscopic Left Liver Resection

May 2, 2014 updated by: Ya-jin Chen, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Recent clinical experience showed that laparoscopic hepatectomy has advantages of minimally invasive compared to open liver resection, however, laparoscopic liver resection is still difficult and risky. Currently it is only carried out in a few large medical centers with slow development. The related research studies were retrospective analysis, there were no prospective randomized controlled multi-center study reported. Because of its relatively simple anatomical advantages, left liver seems to be as the best platform to ensure maximum safety and feasibility of prospective randomized study for laparoscopic hepatectomy .This project intends to carry out a prospective randomized controlled multi-center study to look for evidence of safety, efficacy and minimally invasive of laparoscopic left liver resection, evaluate the long-term efficacy including overall survival, disease-free survival as well as time to disease recurrence for the left liver carcinoma.

Study Overview

Study Type

Interventional

Enrollment (Anticipated)

2

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Guangdong
      • Guangzhou, Guangdong, China, 510120
        • Recruiting
        • Sun Yat-Sen Memorial Hospital,Sun Yat-Sen University
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 70 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Child-pugh A-B
  • Primary hepatocellular carcinoma of the left liver lobe
  • Tumor size ≤5cm in diameter
  • KPS≥60

Exclusion Criteria:

  • Significant abnormal liver function
  • Significant abnormal Heart function
  • Significant abnormal lung function
  • Significant abnormal kidney function

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: laparoscopic hepatectomy
Other: open liver resection

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
amount of bleeding
Time Frame: Participants will be observed for the duration of hospital stay, an expected average of 4 weeks.
Participants will be observed for the duration of hospital stay, an expected average of 4 weeks.
time of operation
Time Frame: Participants will be observed for the duration of hospital stay, an expected average of 4 weeks.
Participants will be observed for the duration of hospital stay, an expected average of 4 weeks.
status of the resection margins
Time Frame: Participants will be observed for the duration of hospital stay, an expected average of 4 weeks.
Participants will be observed for the duration of hospital stay, an expected average of 4 weeks.
bile leakage
Time Frame: Participants will be observed for the duration of hospital stay, an expected average of 4 weeks.
Participants will be observed for the duration of hospital stay, an expected average of 4 weeks.
abdominal adhesion
Time Frame: Participants will be observed for the duration of hospital stay, an expected average of 4 weeks.
Participants will be observed for the duration of hospital stay, an expected average of 4 weeks.

Secondary Outcome Measures

Outcome Measure
Time Frame
overall survival
Time Frame: Participants will be followed for 5 years.
Participants will be followed for 5 years.
disease-free survival
Time Frame: Participants will be followed for 5 years.
Participants will be followed for 5 years.
time to disease recurrence
Time Frame: Participants will be followed for 5 years.
Participants will be followed for 5 years.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

July 1, 2013

Primary Completion (Anticipated)

August 1, 2018

Study Completion (Anticipated)

August 1, 2023

Study Registration Dates

First Submitted

April 29, 2014

First Submitted That Met QC Criteria

May 2, 2014

First Posted (Estimate)

May 6, 2014

Study Record Updates

Last Update Posted (Estimate)

May 6, 2014

Last Update Submitted That Met QC Criteria

May 2, 2014

Last Verified

May 1, 2014

More Information

Terms related to this study

Other Study ID Numbers

  • TLLLR-001
  • 2013005 (Other Grant/Funding Number: Clinical Research Program 5010 of Sun Yat-sen University)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hepatocellular Carcinoma

Clinical Trials on laparoscopic hepatectomy

3
Subscribe